No Data
No Data
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Express News | Jazz Pharmaceuticals PLC - Revolving Credit Facility Maturity Date Extended to November 26, 2029
Express News | Jazz Pharmaceuticals PLC - Amends Credit Agreement to Increase Commitments
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $160 to $207
Jazz Pharmaceuticals Insiders Sold US$1.7m Of Shares Suggesting Hesitancy
Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
No Data
No Data